Treats acute lymphoblastic leukemia. ANDA 40843, held by Pharmachemie. Methotrexate Sodium.
As of Nov 21, 2026, ANDA 40843 (Methotrexate Sodium Preservative Free), held by Pharmachemie, was first approved by FDA on Jan 8, 2010, with 6 approved supplements and 0 published complete response letters.
Methotrexate Injection is a folate analog metabolic inhibitor indicated for: The following neoplastic diseases for the: Treatment of adult and pediatric patients with acute lymphoblastic leukemia as part of a combination chemotherapy regimen. Prophylaxis and treatment of adult and pediatric patients with meningeal leukemia. Treatment of adult and pediatric patients with non-Hodgkin lymphoma. Treatment of adult and pediatric patients with osteosarcoma as part of a combination chemotherapy regimen. Treatment of adults with breast cancer as part of a combination chemotherapy regimen. Treatment of adults with squamous cell carcinoma of the head and neck as a single agent.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jan 8, 2010 | Original application | Approved | None posted |
| Methotrexate Sodium Preservative FreeEQ 1GM BASE/40ML (EQ 25MG BASE/ML) · injectable;injection | Methotrexate Sodium | Rx |
| Methotrexate Sodium Preservative FreeEQ 50MG BASE/2ML (EQ 25MG BASE/ML) · injectable;injection | Methotrexate Sodium | Rx |
| Methotrexate Sodium Preservative FreeEQ 100MG BASE/4ML (EQ 25MG BASE/ML) · injectable;injection | Methotrexate Sodium | Rx |
| Methotrexate Sodium Preservative FreeEQ 250MG BASE/10ML (EQ 25MG BASE/ML) · injectable;injection | Methotrexate Sodium | Rx |
| Jan 14, 2026 | Supplement 13Labeling · Standard review | Approved | None posted |
| Jan 14, 2026 | Supplement 14Labeling · Standard review | Approved | None posted |
| Aug 2, 2021 | Supplement 7Labeling · Standard review | Approved | None posted |
| Aug 2, 2021 | Supplement 11Labeling · Standard review | Approved | None posted |
| Feb 24, 2017 | Supplement 5Labeling · Standard review | Approved | None posted |
| Mar 30, 2012 | Supplement 1Labeling | Approved | None posted |
| Jan 8, 2010 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters